Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Efficacy of LCAR-T2C CAR-T cells

Cell therapy (CAR-T) · Kills target cells, directed at CD4

Phase 1 Most advanced trial (none active)
1 Registered trials

What is Efficacy of LCAR-T2C CAR-T cells?

LCAR-T2C is a CD4-directed CAR-T cell therapy given with lymphoid depletion. It is studied in relapsed or refractory CD4-positive T-cell lymphoma and T-cell leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy (CAR-T)
Targets
CD4 (antigen)
Mechanism
Kills target cells, directed at CD4
Therapy area
Oncology
In trials of
LEGN
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04973527 Phase 1 T Cell Lymphoma Terminated LEGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

T Cell LymphomaT-cell Leukemia

Other drugs acting on CD4

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.